Director of FP&A
PhantomSalary not specified
- Full Time
- Senior (5 to 8 years)
$172,000 – $225,000Compensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Financial Services, BiotechnologyIndustries
Requirements
Candidates should possess a strong financial acumen and demonstrated system experience in financial budgeting and actuals reporting within Life Sciences. Effective interpersonal skills and leadership qualities are essential, along with the ability to build cross-functional business relationships. A hands-on approach and expertise in strategic financial analysis, budgeting, forecasting, and reporting are required.
Responsibilities
The Director of FP&A will lead the annual budget, forecasting, and long-range planning process across all departments, including refining expectations through re-forecasting. They will build models to analyze liquidity, cash forecasting, and strategic options while preparing financial budgets and results for presentations. The role includes developing project-based forecasting to aid strategic discussions, supporting partner collaboration analysis, and working with teams to design and track key performance metrics. Additionally, they will lead quarter-end financial close results, provide regular reporting and variance analysis, partner with the Accounting Team on close processes, and implement enhancements to FP&A processes.
Skills
Budgeting
Forecasting
Financial Modeling
Variance Analysis
Financial Reporting
LRP
Cash Flow Forecasting
Strategic Analysis
Business Development
Cost Analysis
KPI Development
Axsome Therapeutics Inc
Develops therapies for CNS disorders
About Axsome Therapeutics Inc
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.
Key Metrics
New York City, New YorkHeadquarters
2012Year Founded
$430.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees